BioMarin Pharmaceuticals BMRN Net product revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's net product revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's net product revenues — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported net product revenues — total revenues of $760.08M in Q1 2026.
- How has BioMarin Pharmaceuticals's net product revenues — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's net product revenues — total revenues increased by 3.5% year-over-year, from $734.64M to $760.08M.
- What is the long-term trend for BioMarin Pharmaceuticals's net product revenues — total revenues?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's net product revenues — total revenues has grown at a 15.4% compound annual growth rate (CAGR), from $1.78B to $3.17B.
- What does net product revenues — total revenues mean?
- The total amount of money earned from selling pharmaceutical products to customers.
- How do you interpret net product revenues — total revenues?
- An increase indicates successful market penetration and adoption of the company's therapeutic portfolio, while a decrease may signal competitive pressure or loss of market exclusivity.
- How does net product revenues — total revenues compare across companies?
- Comparable to net product sales reported by other specialty biopharmaceutical companies focusing on rare diseases.